Warfarin

Warfarin doesn't thin the blood instantly — it disables a vitamin-dependent clotting factory that takes days to wind down. Misunderstanding that delay costs patients dearly.

Warfarin inhibits vitamin K epoxide reductase, the enzyme that recycles vitamin K into its active form. Without active vitamin K, the liver cannot produce functional clotting factors II, VII, IX, and X (plus proteins C and S). Because warfarin blocks production rather than destroying existing factors, its full anticoagulant effect takes 3–5 days — the time needed for circulating factors to naturally degrade. Factor VII drops first (half-life ~6 hours), which is why PT/INR rises early, but true protection against clot propagation requires depletion of factor II (half-life ~60 hours). This is why heparin bridges warfarin during initiation. Monitoring relies on PT/INR. The target INR for most indications — atrial fibrillation, DVT/PE treatment, and mechanical heart valves — is 2.0–3.0. High-risk mechanical valves (e.g., mitral position, older-generation valves) may target 2.5–3.5. INR is checked frequently during dose titration and at regular intervals once stable. Dietary vitamin K intake (leafy greens) must remain consistent — not eliminated — because sudden changes shift the INR unpredictably. Warfarin is indicated for long-term anticoagulation in atrial fibrillation, venous thromboembolism, and mechanical heart valves.

Key Distinctions

Don't confuse PT/INR (warfarin monitoring) with aPTT (heparin monitoring) — this is the most common pharmacology swap on exams. Students think the patient should avoid all vitamin K foods; the correct teaching is to keep intake consistent. The early rise in INR reflects factor VII depletion, not full anticoagulation — that's why bridging with heparin is necessary, not optional.

Clinical Pearl

Think '2, 7, 9, 10 — takes time to win': warfarin blocks four clotting factors that need vitamin K, and the effect builds over days, not hours.